Four Analyses of Three-Year Clinical Data Suggest CYPHER Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease

VIENNA, Austria, September 05, 2007 /PRNewswire/ -- Four analyses of three-year follow-up data showed that the CYPHER(R) Sirolimus-eluting Coronary Stent may be considered an appropriate alternative to bypass surgery in patients with blockages in two or more coronary arteries (multivessel disease). The analyses were presented this week at the European Society of Cardiology Congress 2007 (ESC Congress 2007).

Three of these analyses sought to assess the long-term impact of the CYPHER(R) Stent when the patient with multivessel disease was also diabetic, the length of the blockage was more than 100 mm or the arterial blockage was located in a junction between a main artery and a side-branch artery, a type of blockage also known as bifurcation. A fourth analysis reported the overall incidence of stent thrombosis in the data set using the Academic Research Consortium (ARC) definitions.

These analyses based their results on data from the Arterial Revascularization Therapy Study I and II (ARTS I and II Studies). The ARTS I Study was conducted in 1997 and compared the results of a bare metal stent to those obtained with bypass surgery. The ARTS II Study included 607 patients from 45 European centers treated with the CYPHER(R) Stent. Investigators compared the findings for these patients to those from the ARTS I Study, which included 605 patients treated with bypass surgery and 600 treated with a bare metal stent.

"These analyses contribute significantly to medical understanding of clinical outcomes for the CYPHER(R) Stent in patients with multivessel disease, who remain one of the most complex patient populations with coronary artery disease to treat," said Principal Investigator Patrick W. Serruys, M.D., Ph.D., from Thoraxcenter, Erasmus Medical Center in The Netherlands, who presented one of the analyses at the congress.

In the subgroup analysis of diabetic patients (367 patients or 20 percent of the total ARTS I and II patient populations), clinical investigators found similar rates of freedom from major adverse cardiac and cerebrovascular events (MACCE) for the CYPHER(R) Stent and bypass surgery out to three years of follow-up. This finding is significant as MACCE -- comprised of death, stroke, myocardial infarction (heart attack) and the need for revascularization (re- treatment) of the blocked artery -- at one-year follow-up was the primary endpoint of the ARTS II Study. Specifically, 72.1 percent of the diabetic patients who received the CYPHER(R) Stent remained free of MACCE three years after the procedure, compared to 82.2 percent of the patients in the bypass surgery arm (p=0.09). Additionally, the CYPHER(R) Stent performed significantly better than the bare metal stent arm during the same endpoint, as 52.7 percent of the patients who received a bare metal stent did not experience a MACCE event after three years. The difference between the CYPHER(R) Stent arm and the bare metal stent arm reached statistical significance (p=0.0003).

Clinical investigators also reported no significant impact on MACCE when CYPHER(R) Stents were implanted in patients with blockages that measured more than 100 mm in length (20 percent of the ARTS II patient population). According to this subgroup analysis, 75.8 percent of these patients remained free of MACCE out to three years of follow-up, compared to 82.5 percent of the patients who received CYPHER(R) Stents measuring 100 mm or less in length (p =0.15).

A third analysis showed that implantation of the CYPHER(R) Stent in bifurcations did not affect clinical outcomes. The rate of freedom-from-MACCE for patients who received a CYPHER(R) Stent to treat a bifurcation (53.4 percent of the overall patient population) was 79.8 percent, compared to 81.5 percent when the implantation did not take place in a bifurcation (p=0.61). The clinical investigators also found that neither the type of bifurcation (true/substantial or partial) nor the stent implantation strategy (one- or two-stent implantation) significantly influenced MACCE outcomes. The freedom- from-MACCE rate for true bifurcations was 81.9 percent, compared to 78.1 percent for partial bifurcations (p=0.58). The one-stent implantation strategy produced a freedom-from-MACCE rate of 82.0 percent, compared to 79.3 percent for the two-stent strategy (p=0.60). Bifurcations are associated with increased case complexity.

In addition, the ARTS II Study investigators reported stent thrombosis rates for the CYPHER(R) Stent using the ARC definitions. The definite, definite/probable and definite/probable/possible stent thrombosis rates for the CYPHER(R) Stent at three years were 3.3 percent, 5.3 percent and 6.4 percent, respectively. Stent thrombosis comparisons between the CYPHER(R) Stent and the bare metal stent were not possible as ARC stent thrombosis rates for the ARTS I Study were not available and the ARTS I Study did not track stent thrombosis rates beyond 30 days. The protocol stent thrombosis rate for the bare metal stent arm was 2.8 percent at 30 days of follow-up, while the ARC definite definite/probable and definite/probable/possible stent thrombosis rates for the CYPHER(R) Stent at 30 days were 1.0 percent, 1.5 percent and 1.5 percent, respectively.

In lieu of ARC stent thrombosis rates for the bare metal stent, the clinical investigators pointed out that the rate of myocardial infarction for the CYPHER(R) Stent was significantly lower than that of the bare-metal stent (3.6 percent for the CYPHER(R) Stent versus 6.8 percent for the bare metal stent, p=0.014). In addition, the mortality rate for the CYPHER(R) Stent was numerically lower than that of the bare metal stent, although this difference did not reach statistical significance (3.0 percent for the CYPHER(R) Stent versus 4.0 percent for the bare metal stent, p=0.33). These rates favored the CYPHER(R) Stent in spite of the fact that the patients treated with the drug- eluting stent were significantly more complex than the patients treated with the bare metal stent.

"The results from ARTS II are excellent for the CYPHER(R) Stent in very complex patients. The ARTS I and II Studies were designed to provide valuable information to help physicians evaluate how to best improve clinical outcomes and increase the quality-of-life of patients with multivessel disease," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Corporation. "Their results add to the large body of existing evidence assessing the performance of the CYPHER(R) Stent in a wide range of patient populations."

In the United States, the CYPHER(R) Stent is indicated for de novo lesions less than 30 mm in length in native coronary arteries between 2.5 mm and 3.5 mm in diameter. It does not have an approved indication for patients with multivessel disease, diabetes or blockages located at a bifurcation.

The ARTS II Study is sponsored by Cordis Corporation.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.

For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at www.cypherstent.com.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com.

*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth Pharmaceuticals.

CONTACT: Christopher Allman of Cordis Corporation, +1-305-586-6024, or; or Todd Ringler of Edelman, +1-617-872-1235, or, for Cordis Corporation callman1@crdus.jnj.com todd.ringler@edelman.com

Web site: http://www.cordis.com/http://www.cypherstent.com/

Ticker Symbol: (:JNJ)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: September 2007

View comments

Hide
(web2)